Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Miglustat (Primary)
- Indications Gangliosidoses; Tay-Sachs disease
- Focus Therapeutic Use
- Acronyms Syner-G
- 19 Jun 2018 Planned End Date changed from 1 Mar 2019 to 31 Aug 2019.
- 19 Jun 2018 Planned primary completion date changed from 1 Mar 2019 to 31 Aug 2019.
- 24 Oct 2017 Status changed from active, no longer recruiting to recruiting.